Aetna Vagus Nerve Stimulation Coverage Update

Coverage and Medical Necessity Criteria

Initial implant coverage

Covered when ALL of the following are met

Focal seizures (partial-onset)

Device: Use of an implantable vagus nerve electrical stimulator with lead placed on the left vagus nerveleft-sided lead placement
Electronic analysis of an implanted neurostimulator pulse generator system is considered medically necessary when criteria are met

Lennox-Gastaut syndrome: Member has Lennox-Gastaut syndrome refractory to optimal anti-epileptic medications and/or surgical intervention (e.g., corpus callosotomy or lesional epilepsy surgery), or has debilitating medication side effectsrefractory despite optimal therapy

No history of bilateral or left cervical vagotomy required

Replacement/Revision

Covered when ALL of the following are met

Replacement/Revision: Replacement or revision of a vagus nerve therapy system or handheld magnet is covered if the original system or magnet met medical necessity criteria and is no longer under warranty and cannot be repairedoriginal system met criteria

Includes replacement external recharging systems and patient programmers as listed in HCPCS when selection criteria are met

Coverage summary by indication

Summary of evidence and inferred coverage implications from cited assessments and reviews:

Epilepsy: VNS is associated with ≥50% seizure reduction in a substantial proportion of children and in patients with Lennox‑Gastaut syndrome based on pooled Class III studies and large case series; it may be considered as an adjunctive therapy for refractory partial‑onset seizures and LGS.

See AAN review for pooled responder estimates and infection risk in children.

Treatment‑Resistant Depression (TRD): Randomized short‑term trials did not demonstrate definitive short‑term efficacy; longer‑term open studies suggest potential benefit but major technology assessments and CMS have concluded evidence is insufficient and CMS has a national non‑coverage determination for TRD.

Rigorous psychiatric evaluation and strict definitions of treatment resistance are emphasized in assessments.

Other indications: Multiple pilot studies and early trials report signals for diverse conditions (headache disorders, inflammatory diseases, gastroparesis, behavioral disorders, etc.) but evidence is preliminary; these uses are generally considered investigational pending well‑designed randomized trials.

Evidence summaries (no explicit coverage criteria)

Evidence-based effectiveness and safety summaries (no formal policy criteria in these chunks):

Epilepsy evidence summary: Pooled analyses and large series report approximately ≥50% seizure reduction in ~55% of children with partial or generalized epilepsy and similar pooled responder rates in Lennox‑Gastaut syndrome; effectiveness may increase over time; infection risk at the implantation site is higher in children.>=50% seizure reduction

Based on AAN review and large consecutive series; permanent vagus nerve injury reported in case series (~2.8%).

Headache and nVNS evidence: Randomized trials of noninvasive VNS demonstrate abortive efficacy in episodic migraine and episodic cluster headache subgroups, but not consistently in chronic forms; PRESTO and Goadsby (2018) provide key randomized data.

Heterogeneity in protocols and sham device activity may affect interpretation.

Status epilepticus evidence: Systematic review found low‑quality evidence (case series) suggesting VNS may terminate refractory status epilepticus in some cases, but evidence is insufficient to recommend routine use.

Coverage-related evidence summaries

Evidence-supported contexts and study findings from this document segment:

Episodic cluster headache (eCH): Randomized trials (Goadsby 2018; Silberstein 2016) demonstrated acute nVNS superiority versus sham in episodic cluster headache subgroups (e.g., pain‑free at 15 minutes in eCH subgroup).

Supports acute nVNS efficacy for eCH subgroup analyses.

Chronic cluster headache (cCH): Acute nVNS trials did not show benefit in chronic cluster headache subgroups; however, PREVA showed that adjunctive prophylactic nVNS reduced weekly attack frequency versus standard of care in an open‑label randomized design with limitations.

Acute efficacy not demonstrated for cCH; prophylactic adjunctive data limited by study design.

Episodic migraine (acute): PRESTO randomized trial (n=248) showed nVNS superior to sham for pain freedom at 30 and 60 minutes and other secondary endpoints, supporting abortive use in episodic migraine attacks.

Findings tempered by device/sham considerations and protocol heterogeneity.

Evidence summaries relevant to coverage

Summary of evidence‑based clinical findings relevant to coverage decisions

Migraine - nVNS (acute): PRESTO and related analyses demonstrated that nVNS provides significantly greater pain‑free and pain‑relief rates at early time points versus sham for episodic migraine with good tolerability and no serious device‑related adverse events reported in these trials.

Interpretation limited by sham device activity and medication‑use restrictions in trials.

Migraine and cluster headache - general: Multiple RCTs (ACT‑1, ACT‑2, PREVA, PRESTO) and cohort studies report efficacy of nVNS for abortive use in episodic migraine and episodic cluster headache; chronic forms responded less robustly.

Heterogeneous protocols and outcome measures limit comparability.

Epilepsy - VNS: AAN systematic review and large series support VNS as a palliative adjunctive therapy for treatment‑resistant epilepsy with pooled responder rates around 55% and potential mood benefits in adults; children have higher implantation‑site infection risk.>=50% seizure reduction in ~55% (pooled)

Initial coverage — VNS paired with rehabilitation (implantable)

Covered when ALL of the following are met

VNS paired with rehabilitation (Vivistim/implantable) - candidate criteria: 1) Patient has persistent moderate‑to‑severe upper‑limb motor deficits associated with chronic ischemic stroke; 2) Stroke is in the chronic phase consistent with pivotal trial enrollment (subjects were at least ~9 months post‑ischemic stroke); 3) VNS is provided as an adjunct to a structured rehabilitation program (in‑clinic sessions followed by a documented home exercise program); 4) Implantation, programming, and use will follow device labeling and clinician training, with documentation of stimulation settings and training for home magnet activation; 5) No contraindications to implantation (e.g., prior bilateral or left cervical vagotomy or planned diathermy).

Derived from Vivistim FDA indication and pivotal RCT protocol; FMA‑UE response and device programming documentation should be included with requests.

Investigational or insufficient evidence

Not established / investigational coverage groups

Experimental or investigational indications: Use of VNS (invasive) or noninvasive VNS modalities for inflammatory disorders, most psychiatric disorders other than established indications, many non‑neurologic indications (e.g., cancer immunomodulation, gastroparesis, severe dysphagia, myocardial I/R injury), and unpaired VNS use for stroke remain investigational or have insufficient evidence for routine coverage; coverage may be considered only in the context of clinical trials or case‑by‑case review with supporting evidence.

Multiple systematic reviews and preclinical/early clinical reports describe promising but preliminary data; larger randomized, sham‑controlled trials are required.

VNS + rehabilitation for post-stroke upper extremity dysfunction

Summary of evidence supporting VNS paired with rehabilitation for upper extremity recovery after ischemic stroke

Evidence components: Randomized controlled trials and meta‑analyses report that VNS paired with rehabilitation produces statistically significant improvements in FMA‑UE scores compared with rehabilitation alone (MDs and pooled estimates vary; clinically meaningful improvement rates higher in VNS arms), with no consistent signal for increased serious device‑related adverse events in RCTs.FMA‑UE mean differences reported across meta‑analyses roughly 3.1 to 7.06 points; clinically significant recovery often defined as >=6 points

Pivotal RCT (MT‑ST‑03) reported a clinically meaningful FMA‑UE response (47% vs 24% at 90 days); long‑term effectiveness and optimal stimulation parameters require further study.

Experimental or investigational indications

Indications with limited evidence (small case series, single-case reports, pilot studies, or preclinical data)

Emerging uses: VNS/tVNS/nVNS have been reported in small case series or pilot studies for indications including cancer immunomodulation, primary Sjogren's syndrome fatigue, severe dysphagia after lateral medullary infarction, gastroparesis, myocardial ischemia‑reperfusion injury, and behavioral symptoms in Prader‑Willi syndrome; evidence consists largely of small, uncontrolled, or preclinical studies.evidence limited to animal studies, small pilot trials, or single‑case reports

Authors consistently call for larger sham‑controlled randomized trials before routine clinical adoption.

Emerging/Investigational Indications — evidence summaries

Summary of evidence and limitations for investigational or emerging VNS applications

Prader‑Willi syndrome (t‑VNS): A non‑blind single‑case repeated measures study in 5 subjects reported reduced frequency and severity of temper outbursts after ~9 months of daily 4‑hour t‑VNS; effects worsened when stimulation was reduced; no serious safety issues reported.n=5; 12 months treatment; 4 hours/day

Authors note lack of sham control, small sample, and call for replication with sham‑controlled trials.

Vestibular migraine (nVNS): A retrospective chart review (n=18) reported rapid relief of vertigo and headache in most treated acute VM patients, but findings are preliminary and subject to placebo effect and selection bias.n=18

Randomized sham‑controlled trials required.

COVID‑19 / ARDS (aVNS): Small pilot randomized ICU study (n=5 treated) showed reductions in inflammatory markers (CRP, TNF‑alpha, D‑dimer) and increases in IL‑10 over 7 days, but clinical outcomes were not interpretable given very small sample size.

Vagus nerve stimulation (implantable VNS and transcutaneous approaches) has been evaluated for a wide range of indications beyond refractory focal epilepsy and Lennox‑Gastaut syndrome. The policy lists these other uses as experimental or investigational because effectiveness has not been established. Examples include: Addictions; Alzheimer disease; anxiety disorders; atonic seizures; atrial fibrillation; autism; bipolar disorder; bulimia nervosa; cancer; cerebral palsy; Crohn’s disease; chronic headaches including migraine and cluster headache; cognitive impairment associated with Alzheimer’s disease; coma; COVID‑19; depression (including postpartum depression); Dravet syndrome; dysphagia; eating disorders; essential tremor; fibromyalgia; gastroparesis; generalized motor seizures and generalized epilepsy syndromes; heart failure; hemicrania continua; impaired glucose tolerance/pre‑diabetes; inflammation and immune‑mediated disorders; intractable hiccups; juvenile myoclonic epilepsy; migraine headaches; mood disorders; narcolepsy; obesity; obsessive‑compulsive disorder; panic disorder; post‑traumatic stress disorder; Prader‑Willi syndrome; rheumatoid arthritis; schizophrenia; Sjogren’s syndrome; sleep disorders; status epilepticus; stroke; tinnitus; Tourette’s syndrome; traumatic brain injury (including post‑TBI pneumonia); and vestibular migraine.

The Centers for Medicare & Medicaid Services (CMS) has issued a national non‑coverage determination for vagus nerve stimulation for treatment‑resistant depression (TRD), concluding that available evidence is insufficient to consider VNS reasonable and necessary for this indication.

When considering atonic (drop‑attack) seizures, published comparative data indicate corpus callosotomy (CC) may achieve higher rates of ≥50% reduction in seizure frequency than VNS (reported pooled rates ~85.6% for CC vs ~57.6% for VNS), and adverse event profiles differ between the procedures; these findings inform selection of surgical options for predominant atonic seizures.

Systematic review evidence for insertion of VNS to treat refractory status epilepticus (RSE) is limited and low quality (Oxford level 4, GRADE D). Although some case series reported cessation of generalized RSE after VNS insertion, authors concluded the evidence is insufficient to recommend VNS for RSE and characterized its use in this setting as investigational.

Narrative reviews and guideline resources cited in the policy note that non‑invasive VNS (nVNS) has produced promising but inconsistent results in migraine disorders. UpToDate summaries referenced in the review do not include VNS as an established therapeutic or prophylactic option for migraine; overall the literature is limited by heterogeneous stimulation protocols, outcome measures, and the need for larger, sham‑controlled trials.

Device labeling and regulatory summaries list absolute contraindications for labeled implantable VNS devices: prior cervical vagotomy (left or bilateral) and procedures involving therapeutic diathermy are contraindications and exclude use of the labeled VNS systems.

Within the excerpted policy text there are no additional explicit exclusion criteria beyond those cited in device labeling and the appendix; the document otherwise summarizes evidence and investigational indications rather than enumerating further exclusions.

The policy appendix specifically states that VNS cannot be used in persons with left or bilateral cervical vagotomy and that VNS is not indicated for persons with other (non‑partial‑onset) seizure types; these surgical and indication‑based exclusions must be screened prior to device consideration.

This Clinical Policy Bulletin is an administrative summary to assist in plan benefit administration and does not constitute a contract. Coverage decisions remain subject to the member’s benefit plan, applicable prior authorization processes, and submission of adequate clinical documentation.

Based on the trial literature and major technology assessments summarized in the policy, VNS for treatment‑resistant depression (TRD) is considered experimental/investigational and not established as medically necessary. Short‑term randomized data did not demonstrate definitive short‑term efficacy, open‑label and observational datasets are inconclusive, and independent technology assessments and CMS concluded evidence is insufficient.

Multiple technology assessments (including BlueCross BlueShield TEC, ARIF, CTAF) concluded that evidence is insufficient to demonstrate effectiveness of VNS for TRD; CMS has formally issued a national non‑coverage determination for VNS in treatment‑resistant depression.

Randomized trials of non‑invasive VNS (nVNS) for cluster headache found mixed results: pooled analyses across episodic and chronic cluster headache did not show superiority to sham, and in combined populations nVNS was not superior. Subgroup and episodic‑only analyses showed benefit for episodic cluster headache but not for chronic cluster headache.

A randomized trial specifically evaluating acute nVNS for chronic cluster headache did not demonstrate efficacy versus sham in the chronic subgroup; while some prophylactic adjunctive studies reported reduced attack frequency with nVNS plus standard care, randomized acute efficacy for cCH was not established.

Investigations of VNS for inflammatory and other non‑neurologic indications are preliminary. Preclinical and early human studies propose modulation of the cholinergic anti‑inflammatory pathway (CAP) and report biomarker changes in small pilots (e.g., Crohn’s disease, rheumatoid arthritis, COVID‑19 ARDS), but evidence remains nascent and these applications are considered investigational pending larger, well‑designed trials.

Systematic reviews and narrative syntheses conclude that VNS and noninvasive VNS approaches lack sufficient high‑quality evidence to support routine use for most psychiatric disorders other than the investigational literature for TRD; therefore, psychiatric indications outside established epilepsy and stroke‑paired indications are not supported by conclusive evidence and are regarded as investigational.

Many studies across non‑stroke indications are small, heterogeneous in design, uncontrolled or pilot in nature. The policy highlights the limited sample sizes, variable stimulation parameters, and open‑label designs that warrant caution in interpreting reported benefits and preclude generalization to routine clinical practice.

Examples of preliminary evidence cited include small or single‑site reports: transcutaneous VNS in Prader‑Willi syndrome (n=5), a chart review of nVNS in vestibular migraine (n=18), an aVNS pilot in critical COVID‑19 patients (n=5) reporting inflammatory biomarker changes, and small taVNS/open‑label studies for postpartum depression and tcVNS pilot studies for PTSD; these small heterogeneous studies are insufficient to establish effectiveness.

Billing and Code Guidance

CPT Codes covered if selection criteria are metCPTCovered

61885	Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to a single electrode array.
64553	Percutaneous implantation of neurostimulator electrodes; cranial nerve.
64568	Incision for implantation of cranial nerve (eg, vagus nerve) neurostimulator electrode array and pulse generator.
64569	Revision or replacement of cranial nerve (eg, vagus nerve) neurostimulator electrode array, including connection to existing pulse generator.
64570	Removal of cranial nerve (eg, vagus nerve) neurostimulator electrode array and pulse generator.
95970	Electronic analysis of implanted neurostimulator pulse generator system (e.g., rate, pulse amplitude and duration, configuration of wave form, battery status, electrode selectability, output modulation, cycling, impedance and patient compliance measurements); simple or complex brain, spinal cord, or peripheral (i.e., cranial nerve, peripheral nerve, autonomic nerve, neuromuscular) neurostimulator pulse generator/transmitter, without reprogramming.
95976	Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with simple cranial nerve neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional.

HCPCS codes covered if selection criteria are metHCPCSCovered

C1767	Generator, neurostimulator (implantable), nonrechargeable.
C1778	Lead, neurostimulator (implantable).
C1816	Receiver and/or transmitter, neurostimulator (implantable).
C1883	Adaptor/ extension, pacing lead or neurostimulator lead (implantable).
L8680	Implantable neurostimulator electrode, each.
L8681	Patient programmer (external) for use with implantable programmable neurostimulator pulse generator, replacement only.
L8685	Implantable neurostimulator pulse generator, single array, rechargeable, includes extension.
L8686	Implantable neurostimulator pulse generator, single array, non-rechargeable, includes extension.
L8687	Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension.
L8688	Implantable neurostimulator pulse generator, dual array, non-rechargeable, includes extension.

HCPCS codes not coveredHCPCSNot Covered

C1827	Generator, neurostimulator (implantable), non-rechargeable, with implantable stimulation lead and external paired stimulation controller.
E0735	Non-invasive vagus nerve stimulator.
E0770	Functional electrical stimulator, transcutaneous stimulation of nerve and/or muscle groups, any type, complete system, not otherwise specified.

ICD-10 codes covered if selection criteria are metICD-10Covered

G40.001 - G40.019	Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, intractable/not intractable, with/without status epilepticus.
G40.101 - G40.219	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, intractable/not intractable, with/without status epilepticus.
G40.811 - G40.814	Lennox-Gastaut syndrome.

ICD-10 codes not covered for CPB indications (examples listed)ICD-10Not Covered

G40.301 - G40.919	Epilepsy [other than partial onset].
G43.001 - G43.919	Migraine.
M96.1	Postlaminectomy syndrome, not elsewhere classified.
U07.1	COVID-19.

No codes listed in this excerptmixed

No codes listed

inv-37: Prior treatment requirement — Failure of optimal anti-epileptic medications and/or surgical intervention

Prior treatment requirementFailure of optimal anti-epileptic medications and/or surgical intervention (e.g., lesionectomy or medial temporal lobectomy)

Medication intolerance alternativePersistent seizures despite optimal therapy or debilitating side effects from anti-epileptic medications

Surgical considerationRefractory after appropriate epilepsy surgery (e.g., corpus callosotomy or lesional epilepsy surgery) when applicable

Vagotomy exclusionNo history of bilateral or left cervical vagotomy prior to VNS implantation

Replacement conditionReplacement/revision covered if original system met medical necessity and is no longer under warranty and cannot be repaired

Prior Authorization, Documentation, and Operational Requirements

Prior Authorization

Prior authorization required

Prior authorization required for implantable VNS systems and related procedures; submit clinical documentation demonstrating member meets selection criteria (e.g., refractory focal seizures or Lennox-Gastaut syndrome despite optimal therapies). Include prior therapy history, psychiatric evaluation when applicable, and evidence supporting device indication. Electronic analysis/programming services billed with applicable CPT codes are covered only when medical necessity criteria are met.

Document prior anti-epileptic medication trials and/or surgical interventions and reason for refractoriness
Provide psychiatric evaluation and definition of treatment resistance for psychiatric indications
Include device implantation and programming records when applicable

Note

Prior authorization — not explicitly specified in all excerpts

Some excerpts in this section do not specify an explicit prior authorization process or codes; follow plan’s general prior authorization procedures and benefit administration rules for submission and review.

If no device‑specific PA pathway exists, use the plan’s standard DME/implantable device PA process
Refer to Clinical Policy Bulletin and member’s benefit plan for operational steps

Prior Authorization

Prior authorization for nVNS trials and evaluation period

For non-invasive vagus nerve stimulation (nVNS) trials (e.g., gammaCore) an evaluation/responder period is commonly used (typical 3–6 months in audits/real-world data). Prior authorization requests for a trial should include documentation of prior conservative treatments, intended evaluation duration, and planned responder assessment metrics.

State planned evaluation period (3–6 months typical) and criteria for continuation
Provide prior conservative therapy documentation and intolerance or inadequate response to medications
Document monitoring plan and follow-up assessments

Prior Authorization

Prior authorization for VNS paired with rehabilitation

Requests for coverage of VNS paired with rehabilitation (e.g., Vivistim Paired VNS System) should document that the candidate population mirrors trial populations and include RCT evidence (FMA‑UE improvements) and safety data to justify implant and therapy pairing.

Include RCT summaries demonstrating FMA‑UE change and responder rates
Document that patient meets device indication (moderate-to-severe upper extremity deficits after ischemic stroke) and rehabilitation plan
Provide implantation and programming notes and planned therapy schedule

Documentation Required

Screen for surgical contraindications

Screen for surgical contraindications prior to authorization and implantation. Confirm absence of left or bilateral cervical vagotomy and avoid diathermy; document contraindications in the chart.

Confirm no history of left or bilateral cervical vagotomy
Document that diathermy will not be used and patient counseling on contraindications

Prior Authorization

Prior authorization requirement — follow plan processes

Follow the plan’s benefit administration and applicable prior authorization processes for final coverage determination; this Clinical Policy Bulletin provides clinical guidance but is not a guarantee of coverage.

Adhere to member-specific benefit limits and prior authorization workflows
Clinical Policy Bulletin guidance does not substitute for plan determination

Billing Rule

Non‑covered device modalities and codes

Non‑covered device modalities include transcutaneous/non‑invasive VNS devices and certain HCPCS/CPT/HCPCS codes (e.g., E0735, E0770, and specific supply codes) when used for indications listed as not covered. Verify coding and coverage status prior to billing.

HCPCS E0735 (Non‑invasive vagus nerve stimulator) — not covered for listed CPB indications
E0770 and selected supply codes listed as not covered — confirm against member benefits

Denial Risk

CMS national non‑coverage for treatment‑resistant depression (TRD)

CMS has concluded VNS is not reasonable and necessary for treatment‑resistant depression (national non‑coverage). Prior authorization requests for VNS for TRD should reference the CMS national non‑coverage determination and include rigorous evidence if requesting exception.

CMS national non‑coverage for TRD (2007) — expect denial unless an exception process is followed
Include comprehensive psychiatric evaluation and justification for any coverage consideration

Note

No explicit administrative authorization or billing-denial triggers specified

In many study areas, no explicit administrative authorization triggers or billing denial criteria are provided in the source text. Use clinical contraindications, lack of evidence, or non‑coverage codes as operational denial risks.

Absent explicit PA triggers in some excerpts — defer to plan PA rules
Denial risks include documented contraindications, lack of documented prior therapies, or national non‑coverage determinations

Denial Risk

Lack of placebo‑controlled evidence for some indications

Several indications lack robust placebo‑controlled evidence (psychiatry, emerging indications); when requesting coverage for investigational uses provide high‑quality evidence or note that absence of controlled trials may lead to non‑coverage.

Document absence of Class I placebo‑controlled trials for depression and other investigational indications
Provide rationale and supporting evidence if seeking coverage for non‑standard indications

Documentation Required

Device contraindications and exclusion criteria

Device contraindications and exclusion criteria must be documented. Common exclusions include prior left or bilateral cervical vagotomy and situations where diathermy is anticipated; list these in the authorization package.

Exclude patients with left or bilateral cervical vagotomy
Document counseling on diathermy precautions and other surgical contraindications

Note

No explicit authorization or prior‑approval timelines specified

No explicit authorization or prior‑approval timelines are provided in some parts of the source; plan operational teams should ensure timelines reflect standard PA processing and any device‑specific surgical scheduling needs.

If no device‑specific timelines exist, apply standard PA turnaround times
Coordinate surgical scheduling with PA approval to avoid delays

Documentation Required

Follow‑up data and monitoring recommended

Studies recommend follow‑up monitoring and reporting: seizure frequency, device complications (including infections), surgical adverse events, and responder status. Include a follow‑up plan in authorization requests.

Provide plan for seizure frequency monitoring and AED management
Include infection surveillance plan, especially in pediatric patients where infection risk is higher

Documentation Required

Responder evaluation and documentation

Responder evaluation documentation is expected for continuation or broader coverage: document baseline and follow‑up outcomes (e.g., attack frequency, FMA‑UE, responder thresholds) and any real‑world evaluation periods used (particularly for nVNS).

Use objective outcome measures (FMA‑UE for stroke, attack frequency for CH/migraine)
Document responder thresholds and duration of observed response

Documentation Required

Pilot and investigational human studies — document limitations

Pilot, small, or investigational human studies cited in the evidence base should be identified in requests; note study limitations (open‑label design, small sample size, lack of sham control) and supply available data when relevant to coverage decisions.

Flag studies that are responder‑selected or lack sham controls
Provide study design, sample size, endpoints, and limitations with requests

Documentation Required

Device implantation and programming documentation

Device implantation and programming must be documented in detail for surgical and reimbursement review: IPG model, laterality of lead placement, programming parameters, recharge system (if applicable), and training/at‑home use arrangements.

Document IPG model, lead placement (left neck for Vivistim), and programming settings
Include clinician software use, wireless transmitter details, and patient magnet use/training

Documentation Required

Clinical evidence to include with requests

Include clinical evidence with authorization requests: RCT summaries, meta‑analyses, and key outcomes (e.g., FMA‑UE improvement for VNS paired with rehab, responder rates for nVNS in cluster headache/migraine) plus adverse event profiles.

Attach RCT publications and meta‑analyses relevant to the requested indication
Summarize primary efficacy endpoints and safety/adverse event data

Documentation Required

Supporting clinical evidence required for investigational indications

Supporting clinical evidence required for investigational or emerging indications should describe study design, sample size, outcomes, and major findings; absence of robust evidence may support denial or classification as experimental/investigational.

Provide study design (RCT vs observational), sample sizes, and outcome measures
Describe limitations and relevance to the member’s clinical status

Note

Bibliographic references included

This section contains bibliographic references and summaries of clinical literature; use these citations to support clinical justification but rely on plan criteria and benefit terms for coverage decisions.

Bibliography and literature summaries are for reference only
Coverage decisions require adherence to plan criteria and benefit provisions

Note

Policy history and last review date

Policy history, last review date, and administrative notes are provided in the bulletin header; consult the Clinical Policy Bulletin and review history for the most recent policy status and effective/next review dates.

Effective date: 2004-02-06; Last review: 02/09/2024; Next review: 02/08/2024
Refer to review history and Clinical Policy Bulletin notes for changes

Step Therapy

Step‑therapy and positioning of neuromodulation

No specific step‑therapy requirements are specified in these excerpts. General positioning: neuromodulation (including VNS and nVNS) is typically considered after failure of established pharmacologic therapies; nVNS may be justified earlier (pre‑refractory) in select populations based on tolerability and evidence.

Document prior conservative therapies tried and reason for inadequacy
Note that nVNS may be considered earlier for episodic migraine or select subgroups when supported by evidence

Documentation Required

Prior conservative therapy — documentation recommended

Prior conservative therapy should be documented for psychiatric, headache, and other non‑epilepsy indications; include medication trials, behavioral therapies, and contraindications/intolerance where relevant.

List prior medication classes, doses, and durations tried
Provide documentation of behavioral or rehabilitative therapies attempted

Documentation Required

Prior conservative therapy documentation for investigational indications

When seeking coverage for investigational or emerging indications, include documentation that standard therapies were tried and failed; lack of such documentation may result in denial as investigational/experimental.

Show prior standard treatments and objective failure/intolerance
Provide rationale for considering device therapy despite investigational status

Definitions and Device Names

inv-80: NeuroCybernetic Prosthesis (NCP) System — FDA-approved implantable VNS system (approved July 16, 1997)

DeviceNeuroCybernetic Prosthesis (NCP) System — FDA-approved implantable VNS system (approved July 16, 1997) consisting of a subcutaneous pulse generator connected to a lead wrapped around the left vagus nerve with a patient-activated magnet

Implant locationPulse generator implanted in upper left chest with lead to left cervical vagus nerve

FunctionDelivers intermittent electrical pulses 24 hours/day; magnet provides additional stimulation when activated by patient

ProgrammingPulse generator programmable for amplitude, frequency, and pulse width to individualize therapy

Adverse effectsCommon side effects include cough, hoarseness, voice changes, and shortness of breath

inv-81: Refractory focal seizures — definition

DefinitionRefractory focal seizures: focal (partial‑onset) seizures that persist despite optimal anti‑epileptic medications and/or surgical intervention, or when medications cause debilitating side effects

Indication contextVNS considered medically necessary for focal seizures meeting this refractory definition

Contraindication noteNot to be used in persons with left or bilateral cervical vagotomy

inv-82: TRD (treatment-resistant depression) — definition used in cited studies

TRD definition (studies referenced)Treatment‑resistant depression defined in cited RCTs as failure to respond adequately to between 2 to 6 research‑qualified antidepressant medication trials prior to enrollment

Trial contextRush et al (2005) randomized patients with 2–6 prior adequate medication trials into masked active vs sham VNS for 10 weeks

Evidence cautionAssessments note variable definitions of adequate prior medication trials and emphasize thorough psychiatric evaluation for patient selection

inv-83: tVNS (transcutaneous VNS) — definition

tVNS definitionTranscutaneous VNS (tVNS): noninvasive stimulation targeting auricular branches of the vagus nerve via the outer ear (e.g., tragus or auditory canal) to activate vagal afferents without implant surgery

Mechanistic evidencetVNS shown in fMRI studies to modulate limbic and brainstem activation patterns consistent with vagal afferent engagement

FeasibilitytVNS considered MRI‑safe in specific device adaptations and is being investigated as a noninvasive alternative to implanted VNS

inv-84: Treatment-resistant epilepsy (TRE) — definition

TRE definitionTreatment‑resistant epilepsy (TRE): epilepsy refractory to antiepileptic drugs for which VNS is used as a palliative adjunctive therapy in reported series

Use caseVNS is considered for TRE as adjunctive therapy when seizures persist despite optimal medical and/or surgical treatment

Evidence levelAAN review supports VNS in children and certain syndromes (Level C evidence) with pooled responder rates reported

inv-85: Noninvasive VNS (nVNS/taVNS) — definition

Noninvasive VNS modalitiesNoninvasive VNS (nVNS/taVNS): transcutaneous stimulation of the vagus nerve using auricular or cervical external devices investigated for epilepsy, headache, atrial fibrillation, metabolic and other indications

ExamplesDevices include handheld cervical stimulators (e.g., gammaCore) and auricular stimulators applied to tragus or ear canal

Regulatory/clinical statusnVNS modalities have RCT evidence in some headache indications but remain investigational for many other uses

inv-86: nVNS — handheld device (e.g., gammaCore) description

Hand‑held nVNS descriptionnVNS: handheld non‑invasive vagus nerve stimulation device (e.g., gammaCore) applied to the neck to stimulate the cervical vagus nerve for acute or prophylactic headache therapy

Clinical findingsPRESTO and other RCTs evaluated handheld nVNS for episodic migraine and cluster headache with evidence supporting acute efficacy in episodic migraine and episodic cluster headache subgroups

TolerabilitynVNS devices generally well tolerated with low incidence of serious adverse events in trials

inv-87: RSE — refractory status epilepticus definition and evidence note

RSE definitionRefractory status epilepticus (RSE): status epilepticus not controlled with first‑ and second‑line therapies

Evidence noteSystematic review (Zeiler 2015) identified low‑quality evidence (Oxford level 4, GRADE D) from case series (n=28 patients) and concluded VNS cannot be recommended for RSE at present

Response rates reportedPooled case-series showed cessation of generalized RSE in 76% of cases but only 25% in focal RSE—insufficient quality for recommendation

inv-88: cholinergic anti-inflammatory pathway (CAP) — definition

CAP definitionCholinergic anti‑inflammatory pathway (CAP): a vagally mediated circuit wherein vagal efferent activity leads to acetylcholine release that inhibits proinflammatory cytokine production (e.g., TNFα) via α7‑nicotinic receptors on macrophages

Mechanistic roleCAP is the hypothesized mechanism for VNS effects on inflammation and is the rationale for investigational use in RA, Crohn's, and other inflammatory conditions

Evidence statusAnimal and early human studies show modulation of inflammatory markers, but the field is nascent and requires systematic clinical trials

inv-89: nVNS (device used for migraine/adjunctive headache therapy) — definition

nVNS for migraine/headachenVNS (non‑invasive cervical stimulation) is a device‑based acute therapy studied for migraine and as adjunctive therapy in headache disorders (e.g., PRESTO, ACT‑1/2, PREVA trials)

Intended useHandheld cervical nVNS applied acutely at attack onset or used adjunctively for prophylaxis in some trials

Clinical evidenceRCTs report benefit in episodic migraine and episodic cluster headache subgroups; chronic forms show less consistent benefit

inv-90: CAP — alternate definition entry

CAP (alternate entry)Cholinergic anti‑inflammatory pathway: a proposed vagus‑mediated neural circuit that modulates innate immune responses and inflammation via acetylcholine‑mediated inhibition of cytokine release

Therapeutic implicationRationale for exploring VNS and aVNS/tVNS in inflammatory and autoimmune diseases such as RA and Crohn's disease

Research statusAuthors emphasize need for standardized protocols and more systematic translational work to harness CAP therapeutically

inv-91: Vivistim System — definition of paired VNS system

Vivistim SystemVivistim Paired VNS System: implantable pulse generator and lead delivering left‑cervical vagus nerve stimulation paired with rehabilitation, programmable via clinician software and usable in‑clinic and at‑home with patient magnet activation per labeling

IndicationFDA‑approved (8/27/2021) for moderate‑to‑severe upper extremity motor deficits associated with chronic ischemic stroke when used with post‑stroke rehabilitation

ComponentsSubcutaneous IPG, lead to left neck electrodes, clinician software and wireless transmitter, and a patient magnet for home activation

inv-92: Noninvasive vagus nerve stimulation modalities — listing of modalities (taVNS / tVNS / transcutaneous VNS / nVNS)

Modalities listedNoninvasive vagus nerve stimulation modalities: taVNS (transauricular), tVNS (transcutaneous), transcutaneous VNS, nVNS (noninvasive cervical) — includes single‑use or reusable stimulators

ExamplesAuricular approaches target tragus or auditory canal; cervical approaches use handheld devices applied to the neck

Clinical contextsModalities investigated across epilepsy, headache, stroke rehabilitation (transcutaneous), inflammatory disorders, and psychiatric conditions

inv-93: Abbreviations for noninvasive modalities — aVNS / taVNS / t‑VNS / nVNS / tcVNS

AbbreviationsaVNS / taVNS / t‑VNS / nVNS / tcVNS — abbreviations used for auricular, transcutaneous auricular, transcutaneous, noninvasive, and transcutaneous cervical vagus nerve stimulation modalities

ScopeAll abbreviations refer to noninvasive or minimally invasive approaches targeting vagal afferents and autonomic pathways

Usage noteAbbreviations are used across the document to describe study types, devices, and stimulation sites

OpenPayer

Vagus Nerve Stimulation

Coverage and Medical Necessity Criteria

Billing and Code Guidance

Prior Authorization, Documentation, and Operational Requirements

Background and Scope

Definitions and Device Names